No evidence of disease activity status over 3 years in a real-world cohort of relapsing remitting MS patients in Germany

DiscussionIn our real-world analysis, we confirm the potential of NEDA for the evaluation and surveillance of MS disease activity, progression and therapy efficacy. Despite highly efficient immunomodulatory treatment, NEDA-3 was only preserved in a minority of patients. Monoclonal antibodies may yield best NEDA rates. Further studies are warranted to evaluate the value of the NEDA concept in real-world settings beyond standardized clinical studies.
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research